169 related articles for article (PubMed ID: 27288073)
1. The Therapeutic Role of d-Cycloserine in Schizophrenia.
Goff D
Adv Pharmacol; 2016; 76():39-66. PubMed ID: 27288073
[TBL] [Abstract][Full Text] [Related]
2. D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.
Goff DC
Curr Neuropharmacol; 2017; 15(1):21-34. PubMed ID: 26915421
[TBL] [Abstract][Full Text] [Related]
3. D-cycloserine: an evolving role in learning and neuroplasticity in schizophrenia.
Goff DC
Schizophr Bull; 2012 Sep; 38(5):936-41. PubMed ID: 22368237
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis.
Heresco-Levy U; Javitt DC
Schizophr Res; 2004 Feb; 66(2-3):89-96. PubMed ID: 15061240
[TBL] [Abstract][Full Text] [Related]
5. Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.
Forsyth JK; Bachman P; Mathalon DH; Roach BJ; Ye E; Asarnow RF
Schizophr Bull; 2017 Sep; 43(5):1123-1133. PubMed ID: 28338977
[TBL] [Abstract][Full Text] [Related]
6. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
[TBL] [Abstract][Full Text] [Related]
7. d-Cycloserine augmentation of cognitive remediation in schizophrenia.
Cain CK; McCue M; Bello I; Creedon T; Tang DI; Laska E; Goff DC
Schizophr Res; 2014 Mar; 153(1-3):177-83. PubMed ID: 24485587
[TBL] [Abstract][Full Text] [Related]
8. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
9. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.
Gottlieb JD; Cather C; Shanahan M; Creedon T; Macklin EA; Goff DC
Schizophr Res; 2011 Sep; 131(1-3):69-74. PubMed ID: 21723096
[TBL] [Abstract][Full Text] [Related]
10. Effects of D-cycloserine on negative symptoms in schizophrenia.
Duncan EJ; Szilagyi S; Schwartz MP; Bugarski-Kirola D; Kunzova A; Negi S; Stephanides M; Efferen TR; Angrist B; Peselow E; Corwin J; Gonzenbach S; Rotrosen JP
Schizophr Res; 2004 Dec; 71(2-3):239-48. PubMed ID: 15474895
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review.
Millan MJ
Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):191-213. PubMed ID: 12769627
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
Goff DC; Tsai G; Levitt J; Amico E; Manoach D; Schoenfeld DA; Hayden DL; McCarley R; Coyle JT
Arch Gen Psychiatry; 1999 Jan; 56(1):21-7. PubMed ID: 9892252
[TBL] [Abstract][Full Text] [Related]
13. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update.
Hofmann SG; Sawyer AT; Asnaani A
Curr Pharm Des; 2012; 18(35):5659-62. PubMed ID: 22632472
[TBL] [Abstract][Full Text] [Related]
14. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
Goff DC; Tsai G; Manoach DS; Coyle JT
Am J Psychiatry; 1995 Aug; 152(8):1213-5. PubMed ID: 7625475
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Shim SS; Hammonds MD; Kee BS
Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
[TBL] [Abstract][Full Text] [Related]
16. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
van Berckel BN; Evenblij CN; van Loon BJ; Maas MF; van der Geld MA; Wynne HJ; van Ree JM; Kahn RS
Neuropsychopharmacology; 1999 Aug; 21(2):203-10. PubMed ID: 10432468
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Tuominen HJ; Tiihonen J; Wahlbeck K
Schizophr Res; 2005 Jan; 72(2-3):225-34. PubMed ID: 15560967
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.
Norberg MM; Krystal JH; Tolin DF
Biol Psychiatry; 2008 Jun; 63(12):1118-26. PubMed ID: 18313643
[TBL] [Abstract][Full Text] [Related]
19. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze.
Pussinen R; Sirviö J
J Psychopharmacol; 1999; 13(2):171-9. PubMed ID: 10475724
[TBL] [Abstract][Full Text] [Related]
20. Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson's disease and studies that need to be performed before clinical trials.
Pawlak CR; Chen FS; Wu FY; Ho YJ
Kaohsiung J Med Sci; 2012 Aug; 28(8):407-17. PubMed ID: 22892161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
